Dabigatran, rivaroxaban, or apixaban versus warfarin in. Media backgrounder for exus and exuk use only the rocket af study. Apixaban versus warfarin in patients with atrial fibrillation nejm. Rocketaf is the first phase iii study assessing the use of rivaroxaban for stroke. As all these factors combine, it has been predicted that the. Rocket afstudie bei patienten mit vorhofflimmern 4. In addition, subjects must have medical evidence of atrial fibrillation within 1 year before and at least one day before the qualifying ecg evidence. The rocket af investigators enrolled 14 264 patients with nonvalvular atrial fibrillation who were at an increased risk of. Rocket af rivaroxaban oncedaily oral direct factor xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation was a phase iii prospective, randomised, doubleblind, double dummy parallel group outcomes study. The rocket af trial rivaroxaban once daily oral direct factor xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation is summarized in. Air force space launch acquisition decisions on the heavy lift launch market. Pdf apixaban versus warfarin in patients with atrial fibrillation.
Prevention of stroke and embolism trial in atrial fibrillation rocket afstudie. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. The rivaroxaban once daily oral direct factor xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation rocket af was a multicenter. New analyses only partly defuse rocket af trial concerns faulty warfarin monitoring didnt undercut results for subgroups, but questions linger. Becker rc, nessel cc, paolini jf, berkowitz sd, fox ka, califf rm. The trial was designed to test for noninferiority, with key secondary objectives of. Noac s are a reasonable alternative to warfarin in af patients with vhd.
Rivaroxaban once daily oral direct factor xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in. Rocket af rivaroxaban once daily oral direct factor xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation, published in the new england journal of medicine in 2011, demonstrated the noninferiority of rivaroxaban compared with warfarin for the primary prevention of stroke or. Rivaroxaban vs warfarin in patients with atrial fibrillation. Atrial fibrillation must be documented by ecg evidence e. The primary outcome was ischemic or hemorrhagic stroke or systemic embolism. Rocket af, 2010 trial summary pdf trial summary a randomised clinical trial investigating the effect of rivaroxaban versus warfarin standard dose in subjects with nonvalvular atrial fibrillation. The j rocket af study was conducted entirely in japan and was designed specifically to evaluate the safety of the 15 mg o.
Stroke prevention in patients with atrial fibrillation effective health. Effects of nonvitamin k antagonist oral anticoagulants versus. Stroke and embolism trial in atrial fibrillation rocket. Rocket af rivaroxaban oncedaily, oral, direct factor xa inhibition. After launching, they automatically alter their direction of. Research to identify patients at risk of af and af related stroke, and the. Chapter 3 airlaunched guided missiles and guided missile launchers guided missiles are selfpropelled objects. However, there was a significant heterogeneity between the three studies due to a lower reduction of icb by rivaroxaban in the rocket af study than by dabigatran or apixaban in the other studies p 0.